Utama › Berat Badan Berlebihan › Indiana › Indianapolis
Kajian klinikal Berat Badan Berlebihan di Indianapolis, IN
13 kajian untuk Berat Badan Berlebihan sedang mencari peserta di lokasi dalam dan sekitar Indianapolis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Mengambil pesertaFasa 3
- IU Health - Riley Physicians Endo-Diab, Indianapolis
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Mengambil pesertaFasa 3
- Midwest Inst For Clin Res, Indianapolis
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Mengambil pesertaFasa 3
- Midwest Inst For Clin Res, Indianapolis
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Mengambil pesertaFasa 3
- Indiana University Health University Hospital, Indianapolis
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Mengambil pesertaFasa 3
- Riley Hospital for Children, Indianapolis
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Mengambil pesertaFasa 3
- Indiana University Health University Hospital, Indianapolis
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Mengambil pesertaFasa 3
- DM Clinical Research - Indianapolis, Indianapolis
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Mengambil pesertaFasa 3
- AURORA-1 Clinical Site, Indianapolis
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Mengambil pesertaFasa 3
- AURORA-2 Clinical Site, Indianapolis
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Mengambil pesertaFasa 2
- Investigators Research Group, Brownsburg · 14 mi jauh
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Mengambil pesertaFasa 4
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield · 14 mi jauh
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Mengambil pesertaFasa 3
- Midwest Inst For Clin Res, Indianapolis
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Mengambil peserta
- Indiana University, Indianapolis
Kajian Berat Badan Berlebihan di bandar lain
- San Antonio, TX34 kajian
- Houston, TX33 kajian
- Chicago, IL28 kajian
- Orlando, FL27 kajian
- Las Vegas, NV23 kajian
- Miami, FL23 kajian
- Atlanta, GA20 kajian
- Dallas, TX20 kajian
- New York City, NY19 kajian
- Jacksonville, FL19 kajian
- Washington, DC19 kajian
- Austin, TX18 kajian
Kajian lain di Indianapolis
- Kanser Paru-paru Bukan Sel Kecil32 kajian
- Kanser (semua jenis)24 kajian
- Kegagalan Jantung23 kajian
- Kanser Payudara20 kajian
- Obesiti20 kajian
- Kanser Metastatik19 kajian
- Kanser Kolorektal18 kajian
- Kanser Ovari17 kajian
- Kanser Paru-paru16 kajian
- Penyakit Kardiovaskular16 kajian
- Diabetes Jenis 114 kajian
- Kanser Endometrium14 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.